In March 2020, the WHO declared COVID-19 to be a global pandemic and since 
December 2020, millions of vaccines have been administered. To date, cases of 
Guillain-Barré syndrome (GBS) following a COVID vaccine (Pfizer, Johnson & 
Johnson, Janssen, AstraZeneca) have been reported. A 61-year-old woman developed 
bilateral asymmetrical lower motor neuron (LMN) facial weakness followed by limb 
symptoms, 10 days after receiving the first dose of AstraZeneca COVID vaccine. 
The second patient was a 56-year-old man who, 9 days after receiving first dose 
of AstraZeneca COVID vaccine, developed bilateral asymmetrical LMN facial 
weakness with limb symptoms. Intravenous immunoglobulin was administered with 
rapid recovery. These cases of GBS following the AstraZeneca COVID vaccine add 
to cohort of patients reported. We flag up to raise awareness of this condition 
post-COVID-19 vaccine and highlight the prominent bifacial involvement. Early 
diagnosis and prompt treatment with intravenous immunoglobulin led to rapid 
recovery.